NASDAQ:BOLD - Audentes Therapeutics News Headlines

Sign in or create an account to add this stock to your watchlist.
$38.50 +0.31 (+0.81 %)
(As of 03/18/2019 04:00 PM ET)
Previous Close$38.19
Today's Range$38.00 - $39.49
52-Week Range$17.95 - $46.18
Volume398,523 shs
Average Volume528,341 shs
Market Capitalization$1.64 billion
P/E Ratio-11.32
Dividend YieldN/A
Beta1.9

Headlines

Audentes Therapeutics (NASDAQ BOLD) News Headlines

Source:
DateHeadline
Audentes Therapeutics (BOLD) Earns "Buy" Rating from HC WainwrightAudentes Therapeutics (BOLD) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - March 18 at 9:45 AM
Head to Head Analysis: Amgen (AMGN) vs. Audentes Therapeutics (BOLD)Head to Head Analysis: Amgen (AMGN) vs. Audentes Therapeutics (BOLD)
www.americanbankingnews.com - March 13 at 12:41 PM
Audentes Therapeutics Inc (BOLD) Given Average Recommendation of "Buy" by BrokeragesAudentes Therapeutics Inc (BOLD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 12 at 2:34 AM
Introducing Audentes Therapeutics (NASDAQ:BOLD), The Stock That Dropped 10% In The Last YearIntroducing Audentes Therapeutics (NASDAQ:BOLD), The Stock That Dropped 10% In The Last Year
finance.yahoo.com - March 8 at 5:42 PM
Audentes Therapeutics (BOLD) Upgraded to Buy: Heres What You Should KnowAudentes Therapeutics (BOLD) Upgraded to Buy: Here's What You Should Know
finance.yahoo.com - March 7 at 10:55 AM
Audentes Therapeutics (BOLD) Upgraded to Buy: Here's What You Should KnowAudentes Therapeutics (BOLD) Upgraded to Buy: Here's What You Should Know
finance.yahoo.com - March 7 at 10:55 AM
Equities Analysts Offer Predictions for Audentes Therapeutics Incs Q1 2019 Earnings (BOLD)Equities Analysts Offer Predictions for Audentes Therapeutics Inc's Q1 2019 Earnings (BOLD)
www.americanbankingnews.com - March 4 at 2:26 AM
Q1 2019 EPS Estimates for Audentes Therapeutics Inc Raised by William Blair (BOLD)Q1 2019 EPS Estimates for Audentes Therapeutics Inc Raised by William Blair (BOLD)
www.americanbankingnews.com - March 4 at 2:26 AM
Audentes Therapeutics Inc (BOLD) Expected to Announce Earnings of -$0.92 Per ShareAudentes Therapeutics Inc (BOLD) Expected to Announce Earnings of -$0.92 Per Share
www.americanbankingnews.com - March 2 at 5:16 PM
Edited Transcript of BOLD earnings conference call or presentation 27-Feb-19 9:30pm GMTEdited Transcript of BOLD earnings conference call or presentation 27-Feb-19 9:30pm GMT
finance.yahoo.com - March 2 at 4:53 PM
Audentes Therapeutics Inc (BOLD) Files 10-K for the Fiscal Year Ended on December 31, 2018Audentes Therapeutics Inc (BOLD) Files 10-K for the Fiscal Year Ended on December 31, 2018
finance.yahoo.com - March 2 at 4:53 PM
Audentes Therapeutics, Inc. (BOLD) Q4 2018 Earnings Conference Call TranscriptAudentes Therapeutics, Inc. (BOLD) Q4 2018 Earnings Conference Call Transcript
finance.yahoo.com - February 28 at 10:11 AM
Audentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Program to Support Patients Living with Rare DiseasesAudentes Therapeutics Recognizes Rare Disease Day by Launching "Be Bold for Courageous Patients" Program to Support Patients Living with Rare Diseases
finance.yahoo.com - February 28 at 10:11 AM
Matthew R. Patterson Sells 21,000 Shares of Audentes Therapeutics Inc (BOLD) StockMatthew R. Patterson Sells 21,000 Shares of Audentes Therapeutics Inc (BOLD) Stock
www.americanbankingnews.com - February 27 at 5:38 PM
Insider Selling: Audentes Therapeutics Inc (BOLD) VP Sells 10,000 Shares of StockInsider Selling: Audentes Therapeutics Inc (BOLD) VP Sells 10,000 Shares of Stock
www.americanbankingnews.com - February 27 at 5:38 PM
Audentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate UpdateAudentes Therapeutics Reports Fourth Quarter 2018 and Full Year Financial Results and Provides Corporate Update
finance.yahoo.com - February 27 at 5:26 PM
Audentes Therapeutics (BOLD) Lifted to "Buy" at Chardan CapitalAudentes Therapeutics (BOLD) Lifted to "Buy" at Chardan Capital
www.americanbankingnews.com - February 25 at 7:48 AM
Audentes Therapeutics (BOLD) Scheduled to Post Earnings on WednesdayAudentes Therapeutics (BOLD) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - February 22 at 8:44 AM
Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019Audentes Therapeutics to Release Fourth Quarter and Full Year 2018 Financial Results and Provide Corporate Update on Wednesday, February 27, 2019
finance.yahoo.com - February 21 at 11:28 AM
Meet Facebooks new neighbor: Cutting-edge cell therapy company lands big East Bay spaceMeet Facebook's new neighbor: Cutting-edge cell therapy company lands big East Bay space
www.bizjournals.com - February 20 at 5:24 PM
Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Audentes Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - February 9 at 9:41 AM
First Week of BOLD March 15th Options TradingFirst Week of BOLD March 15th Options Trading
www.nasdaq.com - February 8 at 5:18 PM
Audentes advancing gene therapy AT132Audentes advancing gene therapy AT132
seekingalpha.com - January 31 at 9:52 AM
Audentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT DesignationAudentes Therapeutics Announces Next Steps in the Development of AT132 to Treat XLMTM Following Collaborative Initial Meeting with FDA Under RMAT Designation
finance.yahoo.com - January 31 at 9:52 AM
Audentes Therapeutics (BOLD) Presents At 37th Annual J.P. Morgan Healthcare Conference - SlideshowAudentes Therapeutics (BOLD) Presents At 37th Annual J.P. Morgan Healthcare Conference - Slideshow
seekingalpha.com - January 9 at 5:18 PM
Audentes Therapeutics Reports on Recent Progress and Outlines 2019 Key PrioritiesAudentes Therapeutics Reports on Recent Progress and Outlines 2019 Key Priorities
finance.yahoo.com - January 7 at 9:43 AM
Audentes Therapeutics appoints Eric B. Mosbrooker as Chief Commercial OfficerAudentes Therapeutics appoints Eric B. Mosbrooker as Chief Commercial Officer
seekingalpha.com - January 3 at 10:01 AM
Audentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial OfficerAudentes Therapeutics Appoints Eric B. Mosbrooker as Senior Vice President and Chief Commercial Officer
finance.yahoo.com - January 3 at 10:01 AM
Audentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare ConferenceAudentes Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 9:40 AM
Need To Know: Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insiders Have Been Selling SharesNeed To Know: Audentes Therapeutics, Inc. (NASDAQ:BOLD) Insiders Have Been Selling Shares
finance.yahoo.com - December 21 at 4:24 PM
Edited Transcript of BOLD earnings conference call or presentation 6-Nov-18 9:30pm GMTEdited Transcript of BOLD earnings conference call or presentation 6-Nov-18 9:30pm GMT
finance.yahoo.com - November 16 at 4:26 PM
These Biopharmas Could Cure Genetic Diseases — At $5 Million ApieceThese Biopharmas Could Cure Genetic Diseases — At $5 Million Apiece
finance.yahoo.com - November 12 at 4:15 PM
Audentes down 21% after Q3 report and pipeline updateAudentes down 21% after Q3 report and pipeline update
seekingalpha.com - November 7 at 4:19 PM
Audentes Therapeutics misses by $0.09Audentes Therapeutics misses by $0.09
seekingalpha.com - November 7 at 9:54 AM
Audentes Therapeutics (BOLD) CEO Matt Patterson on Q3 2018 Results - Earnings Call TranscriptAudentes Therapeutics (BOLD) CEO Matt Patterson on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 7 at 9:54 AM
Audentes Therapeutics (BOLD) Misses Q3 EPS by 9cAudentes Therapeutics (BOLD) Misses Q3 EPS by 9c
www.streetinsider.com - November 7 at 9:54 AM
Audentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate UpdateAudentes Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - November 6 at 4:12 PM
Audentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as ChairmanAudentes Therapeutics Board of Directors Appoints Co-Founder and Chief Executive Officer Matthew R. Patterson as Chairman
finance.yahoo.com - November 5 at 10:14 AM
Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018Audentes Therapeutics to Release Third Quarter 2018 Financial Results and Provide Corporate Update on Tuesday, November 6, 2018
finance.yahoo.com - October 30 at 4:13 PM
Notable Thursday Option Activity: USB, BOLD, SLBNotable Thursday Option Activity: USB, BOLD, SLB
www.nasdaq.com - October 11 at 4:02 PM
Audentes Therapeutics prices common stock offeringAudentes Therapeutics prices common stock offering
seekingalpha.com - October 11 at 9:19 AM
Audentes Therapeutics Announces Pricing of Public Offering of Common StockAudentes Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - October 11 at 9:19 AM
Audentes Therapeutics (BOLD) Plans $150M Offering of Common StockAudentes Therapeutics (BOLD) Plans $150M Offering of Common Stock
www.streetinsider.com - October 10 at 9:34 AM
Your Daily Pharma Scoop: Karyopharms NDA Accepted, Audentes Data PositiveYour Daily Pharma Scoop: Karyopharm's NDA Accepted, Audentes Data Positive
seekingalpha.com - October 8 at 4:01 PM
Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%Audentes Therapeutics (BOLD) Catches Eye: Stock Jumps 7%
www.zacks.com - October 8 at 4:01 PM
Audentes Therapeutics to provide update on interim data from ASPIRO trialAudentes Therapeutics to provide update on interim data from ASPIRO trial
seekingalpha.com - October 5 at 4:04 PM
Audentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle SocietyAudentes Therapeutics Presents New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle Society
finance.yahoo.com - October 5 at 9:35 AM
Audentes Therapeutics to Provide Update on New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, from the 23rd International Annual Congress of the World Muscle SocietyAudentes Therapeutics to Provide Update on New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, from the 23rd International Annual Congress of the World Muscle Society
finance.yahoo.com - October 5 at 9:35 AM
Audentes Therapeutics (BOLD) to Present New Data from ASPIRO at WMSAudentes Therapeutics (BOLD) to Present New Data from ASPIRO at WMS
www.streetinsider.com - September 24 at 4:05 PM
Audentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle SocietyAudentes Therapeutics to Present New Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy, at the 23rd International Congress of the World Muscle Society
finance.yahoo.com - September 24 at 9:47 AM
This page was last updated on 3/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel